UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Employer ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2022 Results Conference Call November 7, 2022 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - CFO Nicole Leber - Investor Relations Conference Call Participants John Vandermosten - Zacks Research Michael King - EF Hutton [Call Start Abruptly] shortly after the call. We issued a press release after market closed today, summarizing our financial results and progress across the company for the third quarter of 2022. A copy of this release i ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Employer | | of Incorporation) | File Number) | Identification No.) | | 1920 McKinney Avenue, ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Nicole Leber – Investor Relations Panna Sharma – Chief Executive Officer David Margrave – Chief Financial Officer Conference Call Participants Operator Good afternoon, everyone. I’m Nicole Leber with Investor Relations here at Lantern Pharma. And welcome to our Second Quarter 2022 Earnings Call. I will be your host for today's call. As a reminder, this call is being recorded and all attendees ar ...

Second Quarter 2022 Operating & Financial Results Conference Call / Webinar August 8th, 2022 4:30 PM Eastern Time NASDAQ :LTRN Forward-Looking Statements 1 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advant ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Emplo ...

First Quarter 2022 Operating & Financial Results Conference Call / Webinar May 3rd, 2022 4:30 PM Eastern Time NASDAQ :LTRN Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages o ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate, Finance & Administrative Coordinator Panna Sharma - President & Chief Executive Officer David Margrave - Chief Financial Officer & Secretary Kishor Bhatia - Chief Scientific Officer & Scientific Consultant Conference Call Participants Nicole Leber Good evening, everybody. I am Nicole Leber with Investor Relations here at Lantern Pharma. And welcome to ou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission File Number) | (IRS Employer | | of Incorporation) | | Identification No.) | | 1920 McKinney Avenue, 7th Floor Dallas, Texas | | 75201 | (Address of Principal Executive ...

Fourth quarter 2021 Operating & Financial Results Conference Call / Webinar March 10th, 2022 4:30 PM Eastern Time NASDAQ:LTRN TODAY'S SPEAKERS Panna Sharma Chief Executive Officer, Chief Scientific Officer Investor Relations President and Director Chief Financial Officer and Secretary David Margrave Dr. Kishor Bhatia Nicole Leber NASDAQ:LTRN 1 LTRN Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and ...